Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta, Precision Therapeutics Amend Co-marketing Deal Again

NEW YORK (GenomeWeb News) – Rosetta Genomics said after the close of the market on Thursday it and Precision Therapeutics have amended their co-marketing deal entered into in July 2012 and revised in October.

As amended, Rosetta has granted Precision the co-exclusive rights to market Rosetta's Cancer Origin test in the US with Rosetta, it said in a document filed with the US Securities and Exchange Commission. Precision must use "commercially reasonable efforts" to market and promote the test, which was formerly called miRview mets2.

Rosetta will record all revenues for sales of the test and is responsible for sample collection, processing, and billing.

As amended the deal has an initial term of one year and will be automatically renewed for an additional six-month period.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.